Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 14/20 | 0.52 |
| ▸ | KIF23 | Q02241 | 1/20 | 0.47 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PDE6D | O43924 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4044332 | 0.92 | KIF11 (0.52) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3865232 | 0.92 | KIF11 (0.60) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL4059317 | 0.88 | KIF11 (0.63) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL4218137 | 0.87 | KIF11 (0.49) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3869460 | 0.87 | KIF11 (0.68) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3875969 | 0.87 | KIF11 (0.68) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3866876 | 0.87 | KIF11 (0.68) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL3869102 | 0.86 | KIF11 (0.67) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL3869099 | 0.86 | KIF11 (0.66) | KIF11KIF23MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL3887257 | 0.83 | KIF11 (0.75) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781673-B1 | SELECTED FUSED HETEROCYCLICS AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090099210-A1 | ENANTIOMERS OF SELECTED FUSED HETEROCYCLICS AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-7498333-B2 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2009-03-03 | — | — | US | disclosed |
| US-20080293744-A1 | Enantiomers of Selected Fused Pyrimidones and Uses in the Treatment and Prevention of Cancer | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080153854-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20070249636-A1 | Selected Fused Heterocyclics and Uses Thereof | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20060063751-A1 | Novel fused heterocycles and uses thereof | ASTRAZENECA AB (SE) | 2006-03-23 | — | — | US | disclosed |
| US-20060041128-A1 | Selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249636-A1 | Selected Fused Heterocyclics and Uses Thereof | SDHA, CYP11B2, NQO1 | KIF11 2056/4885KIF23 2014/4885MAP1LC3B 2465/4885 |
| US-20060063751-A1 | Novel fused heterocycles and uses thereof | RB1, CDK19, PRMT9 | KIF11 1978/4885KIF23 2194/4885MAP1LC3B 3998/4885 |
| US-20080153854-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | RB1, CDK19, PRMT9 | KIF11 1978/4885KIF23 2194/4885MAP1LC3B 3998/4885 |
| US-20080293744-A1 | Enantiomers of Selected Fused Pyrimidones and Uses in the Treatment and Prevention of Cancer | DHFR, DPYD, TYMS | KIF11 3865/4885KIF23 3813/4885MAP1LC3B 4356/4885 |
| US-20060041128-A1 | Selected fused heterocyclics and uses thereof | SDHA, CYP11B2, NQO1 | KIF11 2056/4885KIF23 2014/4885MAP1LC3B 2465/4885 |
| US-20090099210-A1 | ENANTIOMERS OF SELECTED FUSED HETEROCYCLICS AND USES THEREOF | CYP11B2, HCCS, CYP11B1 | KIF11 3171/4885KIF23 3405/4885MAP1LC3B 3465/4885 |
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | CYP11B2, HCCS, CYP11B1 | KIF11 3171/4885KIF23 3405/4885MAP1LC3B 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.